

New impact report reveals radiotherapy's role in cancer care

Sixteen global oncology leaders call for radiotherapy to be prioritized, describing it as clinically advanced, cost-effective and underutilized

STOCKHOLM – Elekta (EKTA-B.ST) today announced the release of the “[2025 Impact Report, Precision Targeting, Global Impact: Cancer Radiotherapy in the 21st Century](#)”, calling for broader adoption, proper reimbursement and global access to advanced radiotherapy to meet the demands of modern cancer care.

Drawing on data, insights from clinical experts and patient experiences, the report demonstrates how radiotherapy is improving outcomes in brain, breast, gynecologic, head and neck, lung, pancreatic, prostate and renal cancers. It highlights innovations like adaptive radiotherapy, which will drive greater precision, help safeguard healthy tissues and enhance quality of life for patients. It also illustrates radiotherapy's role as a standalone treatment and in combination with other therapies such as chemotherapy and immunotherapy.

“We supported the development of this report to bring together leading voices in oncology and highlight the tangible progress being made in radiotherapy,” says Elekta President and CEO Jakob Just-Bomholt. “With new data, technological innovation and direct experience from institutions implementing advanced treatment strategies, the piece offers a timely perspective on how radiotherapy is evolving and what is needed to ensure its benefits reach patients.”

Anthony Paravati, MD, MBA, executive medical director of the oncology service line and chief of radiation oncology at Kettering Health, and contributor to the report, specializes in head and neck cancers where anatomical changes during treatment compromise precision. “In these cases, adaptive radiotherapy is not a luxury, it is a necessity. AI-enabled workflows and real-time imaging allow us to adjust treatment plans with confidence, improving consistency and protecting critical structures. These tools are helping us deliver safer, more effective care in some of the most complex cancer cases.”

The report also serves as a resource for individuals with cancer, explaining treatment options and the role of radiation therapy. It includes patient testimonials including one from Mark Meyer, an avid outdoorsman that enjoys travel whenever possible, who received adaptive radiotherapy with the Elekta Unity MR-Linac.

“Having access to technology that precisely targeted my tumor and limited side effects allowed me to complete treatment in just five sessions and focus on recovery,” says Meyer. “I hope my experience shows that with the right care and access to innovative treatments, people can face cancer with both hope and resilience.”

The full report is available at AboutAdaptive.com digital resource for clinicians that offers information about adaptive radiotherapy and the current cancer care landscape.

###



For further information, please contact:

Mattias Thorsson, Vice President, Head of Corporate Communications

Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com

Time zone: CEST: Central European Summer Time

Raven Canzeri, Global Director, Media Relations

Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com

Time zone: ET: Eastern Time

About Elekta

As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com.